Indian Pharmaceutical Supplier to Brazil

Our Indian manufacturing partners include sites that have been audited by ANVISA inspectors and hold valid Certificado de Boas Práticas de Fabricação for the relevant production lines. Because ANVISA inspection is product-line specific rather than a blanket facility approval, we match each enquiry to a manufacturer with the relevant certificate already in place. Where a Brazilian buyer wants a molecule from a site that has not yet been ANVISA-inspected, we coordinate the foreign-site inspection process with the manufacturer, but we are upfront that this is a multi-month commitment rather than a quick fix. We do not misrepresent inspection status.

Sea freight predominantly routes through Santos, the Americas' largest pharmaceutical port and the default consolidation point for our ambient and refrigerated container traffic into Brazil. Itajaí and Paranaguá serve as secondary sea options when Santos congestion adds lead time. For cold-chain and time-critical consignments, air freight runs Mumbai to Guarulhos (GRU) São Paulo as the primary lane, with Galeão (GIG) Rio used where the end-customer base is Rio-state-centric. We confirm the routing with the importer at order acceptance based on consignment temperature profile and onward distribution geography.

Yes. ANVISA requires Module 1, the patient information leaflet, labelling, and the bulk of Module 3 quality documentation in Portuguese. Some annexes, original analytical certificates, and reference documents may be accepted in English subject to Portuguese summary. We work with Brazilian Pharmacopoeia-aware pharmaceutical translators rather than general-purpose translators because terminology consistency matters to reviewer experience. Translation cost is not trivial, but for any product entering the Brazilian market at scale, the investment is justified by the market size and the longevity of the registration once granted.

Federal SUS procurement runs through the Ministério da Saúde with central tenders for high-volume essential medicines, particularly in the HIV, tuberculosis, and oncology programmes. State-level Secretarias de Saúde run their own tenders for state-funded health networks, and the rhythm varies state by state. Private hospital networks — Rede D'Or, Hapvida, Amil and the larger regional groups — operate consolidated procurement desks that buy on commercial terms with a stronger focus on lead-time reliability and lot consistency. We maintain distinct documentation packs and commercial templates for each channel.

We are not US-FDA registered, and for the Brazilian market it does not affect our ability to supply. ANVISA runs its own foreign-site inspection programme and issues its own GMP certification independent of US-FDA status. ANVISA does take SRA approvals into account for certain accelerated pathways, but the dominant route for Indian generic supply into Brazil is direct ANVISA registration backed by ANVISA's own site inspection. Our Indian manufacturing partners hold WHO-GMP certification and, where relevant for the product line, ANVISA Certificado de Boas Práticas de Fabricação.

International commercial invoicing is in USD as standard, with the Brazilian importer handling BRL conversion at their banking counterparty. The Brazilian Real is fully convertible and Brazilian banking infrastructure is mature, so payment flow is not a friction point. Standard terms are letter of credit at sight or documents-against-payment for first transactions, moving to open account on negotiated terms once a relationship is established. Brazilian banks are familiar with pharmaceutical import documentation and the trade finance side runs cleanly when the underlying paperwork is in order.

Yes — biosimilars are one of our core focus categories for Brazil. Indian biosimilar manufacturing capability has matured substantially in oncology, supportive care, and inflammation, and Brazilian demand for biosimilar oncology molecules is structurally import-reliant in segments where domestic production is limited. We supply biosimilar finished forms with cold-chain validated freight from Mumbai through Guarulhos, paired with ANVISA-format Portuguese dossiers, foreign-site inspection certification, and stability data structured to zone IVa requirements. Biosimilar work demands tighter documentation and freight discipline than commodity generics, and we have built our Brazil practice around exactly this.